Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...

Fluticasone furoate, vilanterol 50/25mcg, 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. The ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

DUBLIN--(BUSINESS WIRE)--The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs market is driven ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

The researchers noted that their findings highlight the need to understand the challenges in delivering evidence-based care for chronic obstructive pulmonary disease (COPD). Patients who live in rural ...